$ENTG · ENTEGRIS INC
Entegris filed its 10-Q for Q3 FY2026 (ended September 26, 2026), reporting net sales of $1.006B, a 24.6% increase from $807.1M in the year-ago quarter. Net income more than doubled to $157.8M ($1.03 diluted EPS) from $70.5M ($0.46 diluted EPS). Gross margin expanded 620 basis points to 49.7%, and operating margin reached 22.9% versus 15.2% last year. The balance sheet shows long-term debt declining to $3.26B from $3.70B at year-end 2025.
- Revenue of $1.006B, up 24.6% YoY from $807.1M in Q3 FY2025
- Gross margin expanded to 49.7% from 43.5% a year ago
- Operating income nearly doubled to $230.6M (22.9% margin) vs $122.6M (15.2%)
- GAAP diluted EPS of $1.03 vs $0.46 in the prior-year quarter
- Long-term debt reduced to $3.26B from $3.70B at year-end 2025
Extended-hours trading shows ENTG at $155.66, down 2.71% from the regular-session close of $160.00, suggesting the strong results may have been priced in or overshadowed by broader concerns.
Entegris delivered one of its strongest quarters, with revenue crossing $1B and margins expanding sharply, yet the after-hours selloff suggests the market wanted more.
Entegris's 24.6% revenue growth and 620 bps gross margin expansion reflect strong semiconductor materials demand, outpacing many peers in the chip supply chain. The debt paydown from $3.70B to $3.26B signals improving balance sheet health in a capital-intensive sector.
The filing flags risks including semiconductor demand fluctuations, supply chain reliance on sole/limited-source suppliers, export controls and tariffs, customer concentration, and goodwill impairment risk ($3.95B on balance sheet). Restructuring charges of $11.2M YTD include wind-down of the Life Sciences Fluid Management business.